Can Fite Biopharma

Update in progress

CANF (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Can-Fite BioPharma Ltd is a clinical-stage biopharma company in Israel developing orally bioavailable small-molecule therapeutics for cancer, liver inflammation, and erectile dysfunction. Lead candidate Piclidenoson completed Phase III for psoriasis. Namodenoson is in Phase III for liver cancer, Phase IIa for pancreatic cancer, and Phase IIb for metabolic-associated steatohepatitis. CF602 is preclinical for erectile dysfunction. License with CMS Medical. Based in Ramat Gan; founded 1994. Formerly Can-Fite Technologies Ltd (name change in 2001).

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive